Citigroup
VRPX

Citigroup’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Citigroup’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-49
Closed -$27K – 6793
2022
Q1 		$27K Buy
+49
New +$28.6K ﹤0.01% 5011

Other funds holding VRPX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's VRPX Position: Q2 2022 in Review

Citigroup sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q2 2022, closing a stake of 49 shares — an estimated $27K sold.

Citigroup first reported a position in VRPX in Q1 2022 and held it in 1 quarter. The position peaked at $27K in Q1 2022. 14 funds tracked by Wall St. Rank hold VRPX as of Q2 2022.

  • Citigroup reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citigroup sold 49 Virpax Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $27K.
  • Citigroup first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Citigroup's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $27K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.